Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Storebrand Livsforsikring AS – successful issuance of Restricted Tier 1 Bond

Storebrand Livsforsikring AS ("the Company"), rated A- by S&P, refers to the announcement on 23 August 2021, and has today successfully completed issuance of a Restricted Tier 1 bond issue in the amount of SEK 900 million, with a substantial oversubscription. The Restricted Tier 1 bond has a perpetual tenor with a first call for the Company after 5 years and will have a floating rate coupon of 3M STIBOR + 2.40% p.a. Settlement of the bonds is expected to be 1 September 2021, and the bonds will be applied for listing on Oslo Børs. The bond is expected to be rated BBB- by S&P. The bond

NeoDynamics granted a U.S. patent for its biopsy needle

STOCKHOLM – AUGUST 25, 2021, NeoDynamics AB (publ) (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announced that the Company has been granted a U.S. patent for its needle design employed in the NeoNavia FlexiPulse probe.The patent is an important milestone for the planned commercial launch in the U.S. and strengthens the protection of the NeoNavia biopsy system. The front-loaded, open-tip sampling needle is designed to enable maximum tissue yield, with minimal patient trauma. “This is exciting news for NeoDynamics. We

YIT commences cooperation negotiations in Finland – no reduction needs in production jobs at construction sites

YIT Corporation   Stock exchange release   25 August 2021 at 2:00 p.m.YIT commences cooperation negotiations in Finland – no reduction needs in production jobs at construction sites As YIT announced in its first quarter interim report, the company aims to improve its competitiveness by developing its operating model. The objective of this work is to, among others, optimise resources to support operations and enable efficient strategy execution. The planning of operating model concerns all YIT’s operations and operating countries, excluding Sweden and Russia. As part of the operating

Danske Hypotek: Interim Report January - June 2021

First half-year in briefJanuary – June 2021 ((comparison with January – June 2020 in parentheses) · Operating profit was SEK 536 million (527 million). · Net interest income amounted to SEK 668 million (596 million). · Costs comprised SEK 60 million (68 million). · Reservations for credit losses amounted to SEK 39 million, for the corresponding period in 2020 reversals amounted to SEK 19 million. · Return on equity was 14.5 % (16.1 %). · The CET1 capital ratio was 16.0 % (14.8 %). Danske Hypotek’s covered bonds have the highest credit rating (AAA) from Standard &

Metso Outotec and Duo Group to provide aggregates solutions in the UK

Metso Outotec Corporation’s press release on August 25, 2021, at 13:00 EESTMetso Outotec has appointed Duo Group as a distributor for Metso Outotec’s aggregates solutions in the UK. The distribution agreement covers the current aggregate business serviced directly by Metso Outotec. This includes aggregate processing solutions including crushers and vibrating equipment, crusher wear parts and spare parts as well as commissioning, service contracts and technical support for aggregate quarries in England, Scotland, and Wales. The contract will come into effect in September 2021.   “We are

Puurakentajat to supply solid wood frames for two new schools in Uusimaa in Southern Finland

Puurakentajat Group Oy has been selected as supplier of solid wood frames for two new schools in Uusimaa, Southern Finland. The delivery of the wooden frame to the Helsinki School of Natural Sciences at the Kumpula University Campus will take place in late 2021, and the construction of the largest Swedish-language school in Inkoo in a picturesque location on the banks of the Inkoo River will begin in early 2022. The school children will start in their new premises in Inkoo by the end of 2022and the upper secondary school students of Kumpula University in the autumn of 2023.The Helsinki

Conditioning unit raises quality of lubrication oil

Plug-and-play unit cools and filters lubricant as it circulates, which helps to extend machine service life and cut the need for maintenanceGothenburg, Sweden 25 August 2021: SKF’s Oil Conditioning Unit (OCU) helps to prolong bearing lifetimes by improving the performance of lubricants in service. The plug-and-play unit cools and filters lubrication oil as it circulates. Cooling helps to improve lubricant performance, while filtration removes contaminants. Filtration levels can be selected from coarse to ultra-fine. “All this helps to reduce bearing failures and ensure reliable

Lipum participate at the LSX Nordic Congress

News: Umeå, 25 august, 2021.Lipums CEO Einar Pontén will present Lipum at LSX Nordic Virtual Congress  6-17 September. The LSX Nordic Congress is annual investment and partnering conference for the Nordic life science and healthcare industry.   For further information, please contact:  Einar Pontén, CEOE-post: einar.ponten@lipum.seMobil: +46 70 578 34 95Web: www.lipum.se   About LipumLipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic

Interim report January – June 2021

Strong growth and high rate of acquisitionApril – June 2021 · Net sales increased by 33.9 percent to SEK 2,311 (1,725) million. Organic growth, adjusted for currency effects, was 12.0 (2.3) percent. · EBIT increased to SEK 197 (154) million, which corresponds to an EBIT margin of 8.5 (8.9) percent. · Cash flow from operating activities for the period was SEK 104 (190) million. · Ten acquisitions were made during the quarter, which, on an annual basis, contribute an estimated total sales of SEK 318 million. · Earnings per share for the period amounted to SEK 2.90 (2.38).

Nederman Holding AB resolves to distribute dividends at Extraordinary General Meeting

An Extraordinary General Meeting of Nederman Holding AB (publ) took place on 25 August 2021. The meeting was held only through postal voting, without the possibility to attend in person, in accordance with temporary legislation. In accordance with the Board of Directors’ proposal, the General Meeting resolved to pay a dividend of SEK 1 per share, amounting to SEK 35 093 096 in total. The record date determined for the dividend is Friday 27 August 2021 after which the dividend is expected to be distributed by Euroclear Sweden AB starting on Wednesday, 1 September 2021. For further

Cell Impact reports second quarter results for 2021: Strong growth

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.· Total revenues for the second quarter amounted to SEK 17.8 million (4.8), which is growth of 270% for the quarter. · Operating result was SEK -23.5 million (-13.3). · The Group's result after financial items was SEK -23.8 million (-13.8). · Earnings per share attributable to the shareholders of the Parent Company totaled SEK -0.41 (-0.30). · Equity was SEK 163.9 million (58.4) or SEK 2.79 per share (1.13) as at the balance sheet date. · Debt/equity ratio was 75% (73%)

Trelleborg publishes Green Finance Framework

Trelleborg Group is publishing a Green Finance Framework today. This will enable the Group to issue green bonds under its existing Medium Term Note (MTN) Program. The green bonds will be used to finance projects that continue to support and develop the Group’s ongoing and future energy efficiency initiatives in production and administration. The framework also empowers Trelleborg’s financing activities to become more involved in the Group’s ‘50 by 25’ climate target, whereby the Group will reduce its CO₂ emissions by 50 percent relative to sales by 2025, combined with its vision of net zero

BioStock: Ultimovacs strengthens clinical validation of UV1 in Q2

Q2 was all about increasing momentum in the clinic for Norwegian Ultimovacs. The company’s universal cancer vaccine UV1 has progressed steadily in one of its phase I trials and in its four phase II trials. CEO Carlos de Sousa joined BioStock for a comment on the newly released report.Read the interview with Carlos de Sousa at biostock.se: https://www.biostock.se/en/2021/08/ultimovacs-strengthens-clinical-validation-of-uv1-in-q2/ This is a press release from BioStock - Connecting Innovation & Capital.

Bricknode accelerates international expansion with key hires in the UK

Bricknode today announced the appointment of two UK hires to support international expansion and increasing demand for its cloud banking solutions. Joel Cope joins the Swedish-based fintech company as Head of Marketing and Barry White has been appointed as Sales Manager.Joel Cope, who joins the company as Head of Marketing, will be responsible for expanding Bricknode’s brand presence and market opportunity. Cope brings a wealth of marketing experience having contributed to several rapid-growth companies in the financial services and fintech industries including Thomson Reuters, Moody’s

Invitation to Clas Ohlson’s Q1 presentation on 8 September

Clas Ohlson will publish the interim report for the first quarter 2021/22 on 8 September at 7:00 a.m. CET. A webcasted presentation of the report will be held at 9:00 a.m. CET the same day.Clas Ohlson invites investors, financial analysts and the media to a webcasted presentation of the interim report for the first quarter 2021/22 on Wednesday 8 September at 9:00 a.m. CET where President and CEO Kristofer Tonström and CFO Pär Christiansen will comment on the report. The interim report for the period May to July 2021/22 will be published at 7:00 a.m. CET and the report and presentation

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

York, UK and Uppsala, Sweden (August 25, 2021) Aptamer Group Ltd , the developer of custom affinity tools to enable the life science industry through its proprietary Optimer platform, and Bio-Works Technologies AB , the developer and manufacturer of leading-edge agarose-based purification technologies, today announce that they have entered into an agreement to co-develop a new affinity resin for improved purification and scale up of gene therapy vectors.  Under the agreement, Aptamer Group will develop an Optimer™ ligand capable of

Frontline Colombian team fights COVID-19 with ECMO therapy

Extracorporeal Membrane Oxygenation (ECMO) – providing the body with oxygen when the lungs fail to perform this task – is one of the key pillars in the treatment of severely ill COVID-19 patients. Combined with the professional expertise of the Colombian thoracic surgeon Diego Pardo, it has been an important tool in his efforts to save lives across the region.   As president of the Colombian Association of Thoracic Surgery, Dr. Pardo, also a licensed physician, is one of the country's leading authorities in the area and a pioneer in using ECMO therapy, which is used to keep

Valmet to invest in a new service center in Guangxi, China

Valmet Oyj’s press release on August 25, 2021 at 11:00 a.m. EETValmet will build its fourth service center in China, in the city of Beihai, to further develop its local presence in the fast-growing pulp and paper industry in the Guangxi province. Valmet's new Guangxi Service Center will be in operation by the fourth quarter in 2023. Valmet’s new service center will serve pulp, board, paper and tissue customers close by with main focus on roll maintenance, fiber equipment services and field services including shutdown planning management.   “Guangxi Zhuang Autonomous Region is a fast-

SynAct strengthens IP portfolio – Grant of key European patent covering AP1189

SynAct Pharma AB ("SynAct") today announced that a European patent was granted covering the company’s leading drug candidate AP1189 in methods of treating kidney diseases.SynAct has received information that its European patent EP 3 743 064 B1 was granted on 11 August 2021. The European patent provides exclusivity on the medical use of AP1189 and similar compounds in treating kidney disease, specifically primary nephrotic syndrome, and including membranous nephropathy which is currently being tested in clinical trials. The European patent will now be validated in selected European

Invitation to SAS’ Q3 2021 teleconference

SAS will publish the interim report for the third quarter of the fiscal year 2021 on Wednesday, 1[st] of September 2021, at approximately 08.00 AM (CET). A teleconference and webcast for investors, analysts and media will be held at 10.00 AM (CET). Anko van der Werff, President & CEO and Magnus Örnberg, Executive Vice President & CFO will present and comment the report. The presentation will be held in English via telephone or https://www.sasgroup.net No advance notification is necessary. Dial-in details for the conference call: DK: +45 354 455 77FI: +358 981 710 310NO:

There are no items matching the current filter
There are no more items matching the current filter
Back to top